Ryan D. Morrison

2.3k citations

73 papers · 1.6k indexed · h-index 25

Impact in

Cellular and Molecular Neuroscience top 2%
- Neuroscience and Neuropharmacology Research
- Neuropeptides and Animal Physiology
Biological Psychiatry top 10%

Papers in ⓘ

Molecular Biology 51
- Receptor Mechanisms and Signaling 30
- Pharmacological Receptor Mechanisms and Effects 13
- Ion channel regulation and function 10
- Nicotinic Acetylcholine Receptors Study 4
Cellular and Molecular Neuroscience 40
- Neuroscience and Neuropharmacology Research 38
- Neuropeptides and Animal Physiology 4

Co-authors: J. Scott Daniels (59 shared papers)Craig W. Lindsley (49 shared papers)P. Jeffrey Conn (35 shared papers)Colleen M. Niswender (36 shared papers)Carrie K. Jones (23 shared papers)Anna L. Blobaum (20 shared papers)Thomas M. Bridges (15 shared papers)Frank W. Byers (15 shared papers)
Journals: Bioorganic & Medicinal Chemistry Letters (21 papers)ACS Chemical Neuroscience (10 papers)Journal of Medicinal Chemistry (8 papers)Laboratory Investigation (3 papers)ChemMedChem (2 papers)
Partner nations: United States United Kingdom Russia

In The Last Decade

Ryan D. Morrison

70 papers receiving 1.6k citations

Peers

Countries citing papers authored by Ryan D. Morrison

Since Specialization

Citations

This map shows the geographic impact of Ryan D. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryan D. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryan D. Morrison more than expected).

Fields of papers citing papers by Ryan D. Morrison

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryan D. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryan D. Morrison. The network helps show where Ryan D. Morrison may publish in the future.

Co-authors

The 25 scholars most cited alongside Ryan D. Morrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ryan D. Morrison Line = papers co-authored together Ryan D. Morrison links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 73 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	ML297 (VU0456810), the First Potent and Selective Activator of the GIRK Potassium Channel, Displays Antiepileptic Properties in Mice ACS Chemical Neuroscience ·Kristian Kaufmann, Ian M. Romaine, Emily Days, Conrado Pascual, A. Malik, Liya Yang, Bende Zou, Yu Du, Greg Sliwoski, Ryan D. Morrison, Jerod S. Denton, Colleen M. Niswender, J. Scott Daniels, Gary A. Sulikowski, Xinmin Xie, Craig W. Lindsley, C. David Weaver	2013	125
2	Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model Neuropsychopharmacology ·Ayan Ghoshal, Jerri M. Rook, Jonathan W. Dickerson, G N Roop, Ryan D. Morrison, Nidhi Jalan‐Sakrikar, Atin Lamsal, Meredith J. Noetzel, Michael S. Poslusney, Michael R. Wood, Bruce J. Melancon, Shaun R. Stauffer, Zixiu Xiang, J. Scott Daniels, Colleen M. Niswender, Carrie K. Jones, Craig W. Lindsley, P. Jeffrey Conn	2015	81
3	The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson’s Disease Journal of Pharmacology and Experimental Therapeutics ·Carrie K. Jones, Michael Bubser, Analisa D. Thompson, Jonathan W. Dickerson, N. Turle-Lorenzo, Marianne Amalric, Anna L. Blobaum, Thomas M. Bridges, Ryan D. Morrison, Satyawan Jadhav, Darren W. Engers, Kimberly Italiano, Jacob Bode, J. Scott Daniels, Craig W. Lindsley, Corey R. Hopkins, P. Jeffrey Conn, Colleen M. Niswender	2011	81
4	Metabolism and Distribution of Clozapine-N-oxide: Implications for Nonhuman Primate Chemogenetics ACS Chemical Neuroscience ·Jessica Raper, Ryan D. Morrison, J. Scott Daniels, Leonard L. Howell, Jocelyne Bachevalier, Thomas Wichmann, Adriana Galván	2017	78
5	Design, Synthesis, and Biological Evaluation of Halogenated N-(2-(4-Oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: Discovery of an Isoform-Selective Small Molecule Phospholipase D2 Inhibitor Journal of Medicinal Chemistry ·Robert R. Lavieri, Sarah Scott, Paige E. Selvy, Kwangho Kim, Satyawan Jadhav, Ryan D. Morrison, J. Scott Daniels, H. Alex Brown, Craig W. Lindsley	2010	75
6	Further optimization of the K-Cl cotransporter KCC2 antagonist ML077: Development of a highly selective and more potent in vitro probe Bioorganic & Medicinal Chemistry Letters ·Eric Delpire, Aleksandra Baranczak, Alex G. Waterson, Kwangho Kim, Nathan R. Kett, Ryan D. Morrison, J. Scott Daniels, C. David Weaver, Craig W. Lindsley	2012	68
7	Development of Dual PLD1/2 and PLD2 Selective Inhibitors from a Common 1,3,8-Triazaspiro[4.5]decane Core: Discovery of ML298 and ML299 That Decrease Invasive Migration in U87-MG Glioblastoma Cells Journal of Medicinal Chemistry ·Matthew C. O’Reilly, Sarah Scott, Kyle A. Brown, Thomas H. Oguin, Paul G. Thomas, J. Scott Daniels, Ryan D. Morrison, H. Alex Brown, Craig W. Lindsley	2013	59
8	Discovery of a Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents Journal of Medicinal Chemistry ·Julie L. Engers, Alice L. Rodriguez, Leah C. Konkol, Ryan D. Morrison, Analisa D. Thompson, Frank W. Byers, Anna L. Blobaum, Sichen Chang, Daryl F. Venable, Matthew T. Loch, Colleen M. Niswender, J. Scott Daniels, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte	2015	55
9	Discovery, Synthesis, and Structure–Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄) with Oral Efficacy in an Antiparkinsonian Animal Model Journal of Medicinal Chemistry ·Carrie K. Jones, Darren W. Engers, Analisa D. Thompson, Julie R. Field, Anna L. Blobaum, Stacey R. Lindsley, Ya Zhou, Rocco D. Gogliotti, Satyawan Jadhav, Rocio Zamorano, James W. Bogenpohl, Yoland Smith, Ryan D. Morrison, J. Scott Daniels, C. David Weaver, P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins	2011	50
10	Discovery of (R)-(2-Fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-Hydroxypiperidin-1-yl)methanone (ML337), An mGlu₃ Selective and CNS Penetrant Negative Allosteric Modulator (NAM) Journal of Medicinal Chemistry ·Cody J. Wenthur, Ryan D. Morrison, Andrew S. Felts, Katrina A. Smith, Julie L. Engers, Frank W. Byers, J. Scott Daniels, Kyle A. Emmitte, P. Jeffrey Conn, Craig W. Lindsley	2013	47
11	Chemical Modulation of Mutant mGlu₁ Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics ACS Chemical Biology ·Hyekyung P. Cho, Pedro M. García-Barrantes, John T. Brogan, Corey R. Hopkins, Colleen M. Niswender, Alice L. Rodriguez, Daryl F. Venable, Ryan D. Morrison, Michael Bubser, J. Scott Daniels, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley	2014	45
12	Discovery, Synthesis, and Preclinical Characterization ofN-(3-Chloro-4-fluorophenyl)-1H-pyrazolo[4,3-b]pyridin-3-amine (VU0418506), a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu₄) ACS Chemical Neuroscience ·Darren W. Engers, Anna L. Blobaum, Rocco D. Gogliotti, Yiu-Yin Cheung, James M. Salovich, Pedro M. García-Barrantes, J. Scott Daniels, Ryan D. Morrison, Carrie K. Jones, Matthew G. Soars, Xiaoliang Zhuo, Jeremy Hurley, John E. Macor, Joanne J. Bronson, P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins	2016	39
13	Partial mGlu5 Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects Neuropsychopharmacology ·Robert W. Gould, Russell J. Amato, Michael Bubser, Max E. Joffe, Michael T. Nedelcovych, Analisa D. Thompson, Hilary Highfield Nickols, Johannes P Yuh, Xiaoyan Zhan, Andrew S. Felts, Alice L. Rodriguez, Ryan D. Morrison, Frank W. Byers, Jerri M. Rook, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Kyle A. Emmitte, Craig W. Lindsley, Carrie K. Jones	2015	36
14	Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizure-Like Adverse Events in Rats Involving a Receptor Agonism-Dependent Mechanism Drug Metabolism and Disposition ·Thomas M. Bridges, Jerri M. Rook, Meredith J. Noetzel, Ryan D. Morrison, Ya Zhou, Rocco D. Gogliotti, Paige N. Vinson, Zixiu Xiang, Carrie K. Jones, Colleen M. Niswender, Craig W. Lindsley, Shaun R. Stauffer, P. Jeffrey Conn, J. Scott Daniels	2013	36
15	Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant Glucagon-Like Peptide 1 Receptor (GLP-1R) Positive Allosteric Modulator (PAM) Journal of Medicinal Chemistry ·Lindsey C. Morris, Kellie D. Nance, Patrick R. Gentry, Emily Days, C. David Weaver, Colleen M. Niswender, Analisa D. Thompson, Carrie K. Jones, Chuck W. Locuson, Ryan D. Morrison, J. Scott Daniels, Kevin D. Niswender, Craig W. Lindsley	2014	36
16	Design and Synthesis of N-Aryl Phenoxyethoxy Pyridinones as Highly Selective and CNS Penetrant mGlu₃ NAMs ACS Medicinal Chemistry Letters ·Julie L. Engers, Katrina A. Bollinger, Rebecca L. Weiner, Alice L. Rodriguez, Madeline F. Long, Megan M. Breiner, Sichen Chang, Sean R. Bollinger, Michael Bubser, Carrie K. Jones, Ryan D. Morrison, Thomas M. Bridges, Anna L. Blobaum, Colleen M. Niswender, P. Jeffrey Conn, Kyle A. Emmitte, Craig W. Lindsley	2017	35
17	Targeting Selective Activation of M₁ for the Treatment of Alzheimer’s Disease: Further Chemical Optimization and Pharmacological Characterization of the M₁ Positive Allosteric Modulator ML169 ACS Chemical Neuroscience ·James C. Tarr, Mark Turlington, Paul R. Reid, Thomas J. Utley, Douglas J. Sheffler, Hyekyung P. Cho, Rebecca Klar, Tristano Pancani, Michael T. Klein, Thomas M. Bridges, Ryan D. Morrison, Anna L. Blobaum, Zixui Xiang, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Michael R. Wood, Craig W. Lindsley	2012	33
18	Development of a novel, CNS-penetrant, metabotropic glutamate receptor 3 (mGlu3) NAM probe (ML289) derived from a closely related mGlu5 PAM Bioorganic & Medicinal Chemistry Letters ·Douglas J. Sheffler, Cody J. Wenthur, Joshua Andrew Bruner, Sheridan J. S. Carrington, Paige N. Vinson, Kiran K. Gogi, Anna L. Blobaum, Ryan D. Morrison, Mitchell Vamos, Nicholas D. P. Cosford, Shaun R. Stauffer, J. Scott Daniels, Colleen M. Niswender, P. Jeffrey Conn, Craig W. Lindsley	2012	31
19	Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2 Journal of Medicinal Chemistry ·Andrew S. Felts, Alice L. Rodriguez, Katrina A. Smith, Julie L. Engers, Ryan D. Morrison, Frank W. Byers, Anna L. Blobaum, Charles W. Locuson, Sichen Chang, Daryl F. Venable, Colleen M. Niswender, J. Scott Daniels, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte	2015	29
20	First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers BMC Pharmacology and Toxicology ·Lisa M. Pitchford, John A. Rathmacher, John C. Fuller, J. Scott Daniels, Ryan D. Morrison, Wendall S. Akers, Naji N. Abumrad, Venkataraman Amarnath, Patricia M. Currey, L. Jackson Roberts, John A. Oates, Olivier Boutaud	2019	28

About Ryan D. Morrison

Ryan D. Morrison is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience, Oncology, Cardiology and Cardiovascular Medicine and Physiology, having authored 73 papers that have together received 1.6k indexed citations. Recurring topics across this work include Neuroscience and Neuropharmacology Research (38 papers), Receptor Mechanisms and Signaling (30 papers), Pharmacological Receptor Mechanisms and Effects (13 papers), Ion channel regulation and function (10 papers), Medication Adherence and Compliance (4 papers), Neuropeptides and Animal Physiology (4 papers), Nicotinic Acetylcholine Receptors Study (4 papers) and Pharmaceutical Practices and Patient Outcomes (3 papers). The work is most often cited by research in Cellular and Molecular Neuroscience (900 citations), Biological Psychiatry (55 citations), Molecular Biology (1.0k citations), Family Practice (28 citations) and Physiology (36 citations). Ryan D. Morrison has collaborated with scholars based in United States, United Kingdom and Russia. Frequent co-authors include J. Scott Daniels, Craig W. Lindsley, P. Jeffrey Conn, Colleen M. Niswender, Carrie K. Jones, Anna L. Blobaum, Thomas M. Bridges, Frank W. Byers, C. David Weaver and Kyle A. Emmitte. Their work appears in journals such as Bioorganic & Medicinal Chemistry Letters, ACS Chemical Neuroscience, Journal of Medicinal Chemistry, Laboratory Investigation and ChemMedChem.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact